Patents Assigned to Gradalis, Inc.
-
Publication number: 20140134236Abstract: In certain preferred embodiments, the invention provides methods for treating cancer, which comprise (a) obtaining a specimen of cancer tissue from a patient; (b) obtaining a specimen of normal tissue in the proximity of the cancer tissue from such patient; (c) extracting total protein and RNA from the cancer tissue and normal tissue; (d) obtaining a protein expression profile of the cancer tissue and normal tissue using 2D DIGE and mass spectrometry; (e) identifying proteins that are expressed in such cancer tissue at significantly different levels than in the normal tissue; (f) obtaining a gene expression profile of the cancer tissue and normal tissue using microarray technology and comparing the results thereof to the protein expression profile; (g) prioritizing over-expressed proteins by assessing the connectivity thereof to other cancer-related or stimulatory proteins; (h) designing an appropriate RNA interference expression cassette to, directly or indirectly, modulate the expression of genes encoding sType: ApplicationFiled: November 4, 2013Publication date: May 15, 2014Applicant: Gradalis, Inc.Inventors: David Shanahan, John J. Nemunaitis, Neil Senzer, Phillip B. Maples, Donald Rao
-
Publication number: 20140093888Abstract: The present disclosure generally relates to highly pure plasmid compositions having low, or undetectable, levels of colanic acid and other contaminants made by a process that includes the steps of obtaining a crude lysate of a plasmid DNA from a bacteria that makes colanic acid; treating the partially purified or purified plasmid DNA with a polypeptide that digests colanic acid under conditions that digest the colanic acid; and purifying the plasmid DNA from the digested colanic acid and the colanic acid degrading enzyme by one or more chromatography steps.Type: ApplicationFiled: December 6, 2013Publication date: April 3, 2014Applicant: GRADALIS, INC.Inventor: Nancy Smyth Templeton
-
Patent number: 8647857Abstract: The present disclosure generally relates to processes employing polypeptides having colanic acid-degrading activity. The processes generally involve contacting a biological material with a polypeptide capable of digesting colanic acid. Additional process steps, such as chromatographic separation steps, are also described.Type: GrantFiled: April 30, 2009Date of Patent: February 11, 2014Assignee: Gradalis, Inc.Inventor: Nancy Smyth Templeton
-
Patent number: 8603991Abstract: Methods for treating cancer that include (a) obtaining a specimen of cancer issue from a patient; (b) obtaining a specimen of normal tissue in the proximity of the cancer tissue; (c) extracting total protein from the cancer tissue and normal tissue; (d) obtaining a protein expression profile of the cancer tissue and normal tissue; (e) identifying a group of proteins that are expressed in the cancer tissue at significantly different levels than in the normal tissue; (f) identifying one or more prioritized proteins from the group of proteins, which will serve as the target for an RNA interference molecule (RNAi), which, when provided to a patient, will reduce the expression level of the one or more prioritized proteins using both cleavage-dependent and cleavage-independent pathways of the RNA-induced silencing complex (RISC).Type: GrantFiled: November 17, 2006Date of Patent: December 10, 2013Assignee: Gradalis, Inc.Inventors: David Shanahan, John Nemunaitis, Neil Senzer, Phillip Maples, Donald Rao
-
Publication number: 20130309752Abstract: The present disclosure generally relates to polypeptides having colanic acid-degrading activity and methods of using the same. Polynucleotides encoding such polypeptides are also described. The polypeptides may be used, for example, in processes for degrading colanic acid, processes for the removal of endotoxins from biological samples, and processes for purifying plasmid DNA.Type: ApplicationFiled: July 30, 2013Publication date: November 21, 2013Applicant: GRADALIS, INC,Inventor: Nancy Smyth Templeton
-
Publication number: 20130302407Abstract: The present invention includes compositions and methods for making and using a bifunctional shRNAs capable of reducing an expression of a K-ras gene, e.g., a mutated K-ras gene, wherein at least one target site sequence of the bifunctional RNA molecule is located within the K-ras gene and wherein the bifunctional RNA molecule is capable of activating a cleavage-dependent and a cleavage-independent RNA-induced silencing complex for reducing the expression level of K-ras.Type: ApplicationFiled: May 9, 2013Publication date: November 14, 2013Applicant: GRADALIS, Inc.Inventors: Donald Rao, Zhaohui Wang, John J. Nemunaitis, Neal Senzer
-
Publication number: 20130259927Abstract: The present invention includes compositions and methods of making and using an imaging label comprising an expression vector comprising a promoter; and a nucleic acid insert operably linked to the promoter, wherein the insert encodes one or more short hairpin RNAs (shRNA) capable of inhibiting an expression of a target gene sequence that is a EWS-FLI1 fusion gene, a EWSR1-ERG fusion gene, or both in Ewing's sarcoma via RNA interference; wherein the one or more shRNA comprise a bifunctional RNA molecule that activates a cleavage-dependent and a cleavage-independent RNA-induced silencing complex for reducing the expression level of the target gene.Type: ApplicationFiled: April 2, 2013Publication date: October 3, 2013Applicant: Gradalis, Inc.Inventors: John J. Nemunaitis, Donald Rao, Neil Senzer
-
Publication number: 20130259925Abstract: The present invention includes compositions and methods of making and using an expression vector comprising a promoter and a nucleic acid insert operably linked to the promoter, wherein the insert encodes one or more short hairpin RNAs (shRNA) capable of inhibiting an expression of a SRC-3 gene via RNA interference, wherein the one or more shRNA comprise a bifunctional RNA molecule that activates a cleavage-dependent and a cleavage-independent RNA-induced silencing complex for reducing the expression level of the SRC-3.Type: ApplicationFiled: March 27, 2013Publication date: October 3, 2013Applicants: BAYLOR COLLEGE OF MEDICINE, GRADALIS, INC.Inventors: Donald Rao, Zhaohui Wang, John J. Nemunaitis, Neil Senzer, Bert W. O'Malley, David Lonard
-
Patent number: 8524475Abstract: The present disclosure generally relates to polypeptides having colanic acid-degrading activity and methods of using the same. Polynucleotides encoding such polypeptides are also described. The polypeptides may be used, for example, in processes for degrading colanic acid, processes for the removal of endotoxins from biological samples, and processes for purifying plasmid DNA.Type: GrantFiled: April 8, 2013Date of Patent: September 3, 2013Assignee: Gradalis, Inc.Inventor: Nancy Smyth Templeton
-
Publication number: 20130210118Abstract: The present disclosure generally relates to polypeptides having colanic acid-degrading activity and methods of using the same. Polynucleotides encoding such polypeptides are also described. The polypeptides may be used, for example, in processes for degrading colanic acid, processes for the removal of endotoxins from biological samples, and processes for purifying plasmid DNA.Type: ApplicationFiled: April 8, 2013Publication date: August 15, 2013Applicant: GRADALIS, INC.Inventor: GRADALIS, INC.
-
Patent number: 8460908Abstract: The present disclosure generally relates to polypeptides having colanic acid-degrading activity and methods of using the same. Polynucleotides encoding such polypeptides are also described. The polypeptides may be used, for example, in processes for degrading colanic acid, processes for the removal of endotoxins from biological samples, and processes for purifying plasmid DNA.Type: GrantFiled: April 30, 2009Date of Patent: June 11, 2013Assignee: Gradalis, IncInventor: Nancy Smyth Templeton
-
Publication number: 20130129813Abstract: Compositions and methods for tissue-specific targeted delivery of therapeutic agents through the use of tissue-specific peptidomimetic ligands are disclosed herein. The ligand comprises a composition of formula A-scaffold-A? and one or more hydrophobic anchors covalently linked to the scaffold. The A and A? compounds linked to the scaffold comprise monovalent peptidomimetic compounds wherein each monovalent peptidomimetic compound is selected from the group consisting of fragments IKs, GKs, IDs, GSs, GTs, VSs, TKs, KTs, ARs, KIs, KEs, AEs, GRs, YSs, IRs, and morpholino.Type: ApplicationFiled: October 30, 2012Publication date: May 23, 2013Applicant: GRADALIS, INC.Inventor: Nancy Smyth Templeton
-
Publication number: 20130084331Abstract: A bifunctional shRNA-based composition and methods for knocking down the expression of the PDX-1 oncogene in target cells is described herein. The invention also provides methods to deliver the shRNA-containing expression vectors to target tissues overexpressing the PDX-1 oncogene.Type: ApplicationFiled: December 4, 2012Publication date: April 4, 2013Applicants: BAYLOR COLLEGE OF MEDICINE, GRADALIS, INC.Inventors: John J. Nemunaitis, Donald Rao, F. Charles Brunicardi
-
Publication number: 20130078719Abstract: The present invention relates to certain novel shRNA molecules and methods of use thereof. According to certain embodiments of the present invention, methods for reducing the expression level of a target gene are provided. Such methods generally comprise providing a cell with one or more precursor nucleic acid sequences that encode two or more RNA molecules. A first RNA molecule comprises a double stranded sequence, which includes a guide strand sequence that is complementary to a portion of an mRNA transcript encoded by the target gene. In addition, a second RNA molecule comprises a second double stranded sequence, which includes a second guide strand sequence that is partially complementary to a portion of the mRNA transcript encoded by the target gene. Preferably, the second guide strand sequence comprises one or more bases that are mismatched with a nucleic acid sequence of the mRNA transcript encoded by the target gene.Type: ApplicationFiled: June 29, 2012Publication date: March 28, 2013Applicant: GRADALIS, INC.Inventor: Donald Rao
-
Publication number: 20130078279Abstract: Compositions and methods for cancer treatment are discloses herein. More specifically the present invention describes an autologous cancer vaccine genetically modified for Furin knockdown and GM-CSF expression. The vaccine described herein attenuates the immunosuppressive activity of TGF-? through the use of bi-functional shRNAs to knock down the expression of furin in cancer cells, and to augment tumor antigen expression, presentation, and processing through expression of the GM-CSF transgene.Type: ApplicationFiled: September 7, 2012Publication date: March 28, 2013Applicant: GRADALIS, INC.Inventors: John J. Nemunaitis, Neil Senzer, Phillip B. Maples, Donald Rao
-
Publication number: 20130071928Abstract: The present invention relates to certain novel shRNA molecules and methods of use thereof. According to certain embodiments of the present invention, methods for reducing the expression level of a target gene are provided. Such methods generally comprise providing a cell with one or more precursor nucleic acid sequences that encode two or more RNA molecules. A first RNA molecule comprises a double stranded sequence, which includes a guide strand sequence that is complementary to a portion of an mRNA transcript encoded by the target gene. In addition, a second RNA molecule comprises a second double stranded sequence, which includes a second guide strand sequence that is partially complementary to a portion of the mRNA transcript encoded by the target gene. Preferably, the second guide strand sequence comprises one or more bases that are mismatched with a nucleic acid sequence of the mRNA transcript encoded by the target gene.Type: ApplicationFiled: June 29, 2012Publication date: March 21, 2013Applicant: GRADALIS, INC.Inventor: Donald Rao
-
Publication number: 20130064881Abstract: Compositions and methods to interfere with Androgen Receptor (AR) action based on bifunctional shRNA, targeting the AR and/or expression of SRC derived peptides are disclosed herein.Type: ApplicationFiled: September 7, 2012Publication date: March 14, 2013Applicant: GRADALIS, INC.Inventors: John J. Nemunaitis, Donald Rao
-
Patent number: 8361983Abstract: A bifunctional shRNA-based composition and methods for knocking down the expression of the PDX-1 oncogene in target cells is described herein. The invention also provides methods to deliver the shRNA-containing expression vectors to target tissues overexpressing the PDX-1 oncogene.Type: GrantFiled: October 27, 2010Date of Patent: January 29, 2013Assignees: Gradalis, Inc., Baylor College of MedicineInventors: John J. Nemunaitis, Donald Rao, F. Charles Brunicardi
-
Patent number: 8333988Abstract: Compositions and methods for tissue-specific targeted delivery of therapeutic agents through the use of tissue-specific peptidomimetic ligands are disclosed herein. The ligand comprises a composition of formula A-scaffold-A? and one or more hydrophobic anchors covalently linked to the scaffold. The A and A? compounds linked to the scaffold comprise monovalent peptidomimetic compounds wherein each monovalent peptidomimetic compound is selected from the group consisting of fragments IKs, GKs, IDs, GSs, GTs, VSs, TKs, KTs, ARs, KIs, KEs, AEs, GRs, YSs, IRs, and morpholino.Type: GrantFiled: September 3, 2010Date of Patent: December 18, 2012Assignee: GRADALIS, Inc.Inventor: Nancy Smyth Templeton
-
Publication number: 20120251617Abstract: The present invention includes bifunctional shRNAs capable of reducing an expression of a Stathmin 1 gene; wherein at least one target site sequence of the bifunctional RNA molecule is located within the Stathmin 1 gene, wherein the bifunctional RNA molecule is capable of activating a cleavage-dependent and a cleavage-independent RNA-induced silencing complex for reducing the expression level of Stathmin 1.Type: ApplicationFiled: March 1, 2012Publication date: October 4, 2012Applicant: GRADALIS, INC.Inventors: DONALD RAO, JOHN J. NEMUNAITIS, NEIL SENZER